Deciphering the molecular mechanisms by which ATV prevents CM-associated mortalities, controls CXCL10 and other molecules associated with pathogenesis of the disease could provide new drug targets and efficacious ways to improve the outcome of patients suffering from CM. The gene discussed is NBN; the disease is cutaneous mastocytosis.